Search
Categories
Hot topics close

Novo Nordisk builds cardio claim case for oral semaglutide

Novo Nordisk builds cardio claim case for oral semaglutide
Novo Nordisk's bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has advanced again with new data showing it is safe for the heart. The US requires all new diabetes drugs to have data showing they don't perform".
Similar news
News Archive
  • Redmi
    Redmi
    Budget Redmi 10A launches with up to 128GB storage, price under Rs 10000
    30 Mar 2022
    5
  • Junior Pope
    Junior Pope
    JUST-IN: Actor 'Junior Pope' Is Alive, Says AGN President Rollas
    10 Apr 2024
    3
  • Volkswagen ID
    Volkswagen ID
    VW I.D. Crozz Makes Spy Photo Debut With Production Body
    30 Jul 2019
    1
  • Gagan Narang
    Gagan Narang
    Want to make shooting sport affordable and accessible to all: Gagan Narang
    6 Jul 2019
    3
  • Mask
    Mask
    Spain reintroduces mandatory face masks over COVID concerns
    9 Jan 2024
    94
This week's most popular news